Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2014; 20(6): 1517-1528
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1517
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1517
Table 1 Summary of consensus reports on Helicobacter pylori therapy
Region | Consensus title | Year | 1st line treatment recommendations | Salvage therapy recommendations | Ref. |
South America | 3rd Brazilian consensus | 2013 | PPI + amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 d(Replace amoxicillin with furazolidone 200 mg twice daily for penicillin allergy) | PPI + levofloxacin 500 mg once daily + amoxicillin 1 g twice daily for 10 dorPPI + levofloxacin 500 mg once daily + furazolidone 400 mg once daily for 7-10 dorbismuth-based quadruple therapy for 10-14 d | [7] |
24 countries: United Kingdom United States Spain Italian Germany France Ireland etc. | Management of Helicobacter pylori infection-the maastricht IV/florence consensusreport | 2012 | If clarithromycin resistance rate < 20%:PPI + amoxicillin + clarithromycinorbismuth-based quadruple therapy(Replace amoxicillin with metronidazole for penicillin allergy)If clarithromycin resistance rate > 20%:Bismuth-based quadruple therapyorNon-bismuth quadruple therapy (sequential/concomitant therapy) | 2nd line rescue:if clarithromycin resistance rate < 20%:bismuth-based quadruple therapyorPPI + levofloxacin + amoxicillinif clarithromycin resistance rate > 20%:PPI + levofloxacin + amoxicillin3rd line rescue:antibiotic susceptibility test first | [6] |
Global | Helicobacter pylori in developing countriesWorld Gastroenterology Organization Global Guideline | 2011 | PPI + amoxicillin + clarithromycin(replace amoxicillin with metronidazole for penicillin allergy)orbismuth-based quadruple therapy | Bismuth-based quadruple therapyorPPI + levofloxacin + amoxicillin | [8] |
Asia Pacific | Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection | 2009 | PPI + amoxicillin + clarithromycin for 7 dorbismuth-based quadruple therapy | PPI-amoxicillin-metronidazole_orbismuth-based quadruple therapyorlevofloxacin-based triple therapyorrifabutin-based triple therapy | [1] |
Japan | Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition | 2009 | PPI + amoxicillin + clarithromycin for 7 d | 2nd line rescue:PPI + amoxicillin + metronidazole for 5-10 d3rd line rescue:PPI + amoxicillin + levofloxacin | [9] |
Latin America | Latin-American Consensus Conference on Helicobacter pylori infection | 2000 | Omeprazole 20 mg, or lansoprazole 30 mg, or pantoprazole 40 mg, or rabeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1000 mg twice a day for 7–14 d (preferably 10 d) | No specific recommendations | [10] |
-
Citation: Song M, Ang TL. Second and third line treatment options for
Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 - URL: https://www.wjgnet.com/1007-9327/full/v20/i6/1517.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i6.1517